Not for people.

A study published in Nature Aging identified Bifidobacterium pseudocatenulatum as a bacterium that was less abundant with increasing age across Chinese human cohorts. Researchers then gave the bacterium to naturally aged mice and reported improvements in intestinal balance, inflammation across several organs, cognitive and movement tests, and broader measures of healthspan.

They also identified a bacterial metabolite called 5-aminovaleric acid betaine, mercifully shortened to 5-AVAB. Giving 5-AVAB to aged mice reproduced some of the benefits seen with the bacterium.

This is fascinating research into probiotics and healthy ageing. It is not evidence that an anti-ageing probiotic slows human ageing, prevents dementia, keeps muscles young or extends human life.

No person received the bacterium or 5-AVAB. The human part of the study was observational; the treatment part happened in mice.

“Helped elderly mice” and “keeps your grandmother young” may live in the same research neighbourhood, but they are not yet sharing a driveway.

The anti-ageing probiotic study at a glance

What did researchers find in people?

The human analysis included a 257-person discovery cohort and a 1,483-person validation cohort. Together, these involved 1,740 Han Chinese adults ranging from 18 to 90 years old.

Researchers examined gut microbiome patterns alongside other biological and clinical information. They described two broad microbiome groupings dominated by either Bacteroides or Prevotella.

Age-related changes were not identical across these gut patterns. Among people with a Prevotella-dominant microbiome, potentially beneficial organisms appeared to decline more rapidly, while microbial genes associated with virulence and antibiotic resistance increased.

One organism stood out across sexes, gut patterns and cohorts: Bifidobacterium pseudocatenulatum. Its abundance was consistently lower with increasing age.

The researchers also developed MicroAge, a microbiome-based model intended to estimate biological ageing patterns. People with more B. pseudocatenulatum tended to show a younger MicroAge profile and more favourable patterns across several clinical indicators.

That is an association. It does not establish that losing this bacterium causes ageing or that adding it back makes a person biologically younger.

Older and younger people differ in diet, medicines, health conditions, activity, living environment and many other factors. Statistical models can adjust for selected variables, but they cannot quietly transform an observational dataset into a randomised human trial while the peer reviewers are making tea.

What happened when aged mice received the bacterium?

The intervention part of the anti-ageing probiotic study used naturally aged male C57BL/6 mice.

After oral supplementation with B. pseudocatenulatum, the researchers reported improvements across several categories:

• better intestinal homeostasis and barrier-related measurements;
• reduced markers of chronic low-grade inflammation;
• less inflammation across organs including the liver, lungs, muscles, kidneys, heart and spleen;
• improved performance in tests of recognition, cognition and motor coordination; and
• an extension of measured healthspan.

Individual mouse experiments used modest group sizes that varied by outcome. For example, published figure information shows approximately 11–15 mice per group for selected motor and recognition tests.

The reporting summary states that behavioural recordings and histological-marker analyses were performed blind. It also notes that only male mice were analysed.

These are meaningful preclinical findings. They suggest that the bacterium may influence several biological systems involved in ageing.

They do not tell us whether the same organism would survive, behave safely or produce a useful effect in an older adult taking medicines, living with chronic illness and occasionally refusing to discuss how little fibre was eaten last Tuesday.

What is inflammaging?

“Inflammaging” describes the persistent, low-grade inflammatory activity often associated with ageing.

It is not the same as the short, protective inflammatory response that helps the body respond to an injury or infection. Instead, it refers to longer-term inflammatory signalling that may interact with metabolic health, immune function, muscle, blood vessels, the brain and other tissues.

The gut microbiome is being studied as one possible contributor. Changes in microbial communities, intestinal barrier function, and bacterial metabolites could influence immune communication throughout the body.

In the new study, B. pseudocatenulatum reduced several inflammatory and cellular-senescence markers in mice. That provides a plausible biological pathway worth investigating.

It does not make an anti-ageing probiotic an established treatment for inflammation in humans. “Inflammaging” is also not a diagnosis to be self-treated after seeing one unusually enthusiastic reel before breakfast.

What is 5-AVAB?

5-AVAB stands for 5-aminovaleric acid betaine. It is a small molecule associated with diet and microbial metabolism.

The researchers identified 5-AVAB as an important metabolite produced in connection with B. pseudocatenulatum. Levels of the metabolite also declined with age in the human data.

When naturally aged mice received 5-AVAB directly, researchers observed improvements in memory-related, movement and mood-related behavioural tests. Markers of chronic low-grade inflammation in several organs were also reduced.

However, 5-AVAB reproduced only part of the bacterium’s broader effects. A living microbe can interact with other organisms, nutrients, the intestinal barrier and immune signalling in ways that one isolated metabolite may not copy completely.

The metabolite also has a complicated metabolic history in earlier research, including reported effects on carnitine handling and fatty-acid oxidation. It should not be treated as an over-the-counter longevity ingredient merely because its abbreviation looks conveniently supplement-sized.

No older adults were given 5-AVAB in this study. There is no established human anti-ageing dose, long-term safety profile or recommended consumer product.

Healthspan is not the same as lifespan

Healthspan usually refers to the period of life spent with better function and fewer ageing-related limitations. Lifespan simply describes how long an organism lives.

The paper describes an extension of healthspan in aged mice, supported by changes in physical, cognitive, intestinal and inflammatory measurements.

This should not be rewritten as “the probiotic makes people live longer”. The study did not test human lifespan, human disability, dementia risk, falls, hospitalisation or quality of life.

A mouse staying on a rotating rod for longer is a useful experimental result. It is not yet evidence that Grandpa can cancel the handrail installation.

Why mouse results cannot be transferred directly to humans

Mice are valuable for studying biological mechanisms because researchers can control their genetics, housing, food and exposures. They can also examine tissues and pathways in ways that would be impractical or unethical in people.

But mice and humans differ in:

• microbiome composition;
• metabolism;
• immune biology;
• diet;
• body size and dosing;
• lifespan;
• medicines and illnesses; and
• the gloriously untidy business of real human life.

Many interventions that look promising in animal models do not produce the same benefit in clinical trials. Some fail because the biology does not translate. Others fail because a useful dose cannot be achieved safely, the effect is too small or the target population is different.

Before anyone can responsibly describe this organism as a human anti-ageing probiotic, researchers would need well-designed clinical trials testing a clearly identified strain, dose, formulation, duration and suitable outcomes.

Species, strain and formulation still matter

Bifidobacterium pseudocatenulatum is a bacterial species. A commercial probiotic contains one or more particular strains prepared in a particular formulation.

Two strains within the same species may differ in their genes, survival, metabolic output and interaction with the host. Storage, dose and delivery format may also change how many living organisms reach the intestine.

The study therefore cannot be used to claim that:

• all bifidobacteria have the same effects;
• any multi-strain probiotic reproduces these findings;
• more strains provide greater anti-ageing benefit;
• a yoghurt or fermented food contains the organism at an effective dose; or
• an unrelated probiotic becomes an anti-ageing probiotic by mentioning the paper in its advertising.

“Probiotic” is a category. It is not a scientific family surname that allows every bacterial cousin to inherit the same research.

Important limitations of the study

This is a sophisticated study combining human microbiome data, multi-omics analysis, predictive modelling, animal experiments and cell research. Several limitations still control what can be claimed:

• The human results were observational and cannot establish cause and effect.
• The human participants were Han Chinese adults, so the findings require validation in other populations, diets and healthcare settings.
• No human participant received B. pseudocatenulatum or 5-AVAB.
• MicroAge is a research model, not a validated consumer or clinical test of how old somebody “really” is.
• The intervention experiments involved naturally aged mice, not people.
• Only male mice were used, limiting conclusions about sex-related biological differences.
• Group sizes for individual mouse outcomes were modest.
• Improved laboratory and behavioural measurements do not automatically predict fewer diseases or longer life in humans.
• The results apply to the tested organism and experimental preparation, not probiotics as a whole.

The research identifies a promising pathway for future investigation. It does not provide a shopping list for a human longevity programme.

What the anti-ageing probiotic study did not prove

The study does not show that taking a probiotic can:

• reverse human ageing;
• extend human life;
• prevent or treat dementia;
• restore memory in older adults;
• improve human balance, strength or mobility;
• prevent frailty;
• treat inflammatory disease;
• replace exercise, a suitable diet or prescribed treatment; or
• produce the same effects with a different species, strain or formulation.

The phrase anti-ageing probiotic is therefore a research headline, not a clinical recommendation.

What actually supports healthy ageing?

Healthy ageing is influenced by genetics, income, social connection, healthcare, diet, physical activity, sleep, tobacco and alcohol exposure, medicines, chronic conditions and environment.

The reliably unglamorous foundations still include:

• regular movement combining aerobic activity, strength and balance work where appropriate;
• a varied eating pattern containing vegetables, fruit, legumes, whole grains, nuts and seeds as tolerated;
• adequate protein suited to age, kidney function and individual needs;
• appropriate vaccination and routine health checks;
• reviewing medicines and fall risks;
• not smoking;
• moderating or avoiding alcohol;
• protecting sleep; and
• maintaining social and mental engagement.

None fits comfortably into a bottle labelled “Ageing: Cancelled”. Biology remains inconsiderately resistant to tidy marketing.

Where do Noster ProBiotics fit?

Noster ProBiotics are refrigerated live culture probiotics intended to support everyday digestive and microbial balance.

Noster ProBiotics were not tested in this study.

We do not claim that Noster reproduces the mouse findings, increases 5-AVAB, reverses ageing, improves cognition, treats inflammation or extends life.

The study is relevant because it illustrates several important principles behind responsible probiotic communication:

• specific organisms may perform specific biological functions;
• microbial metabolites may matter as much as bacterial names;
• human associations are not the same as human treatment evidence; and
• animal results must be tested properly before becoming health claims.

If your goal is general digestive and microbial support, you can learn more about Noster Live Culture Probiotic Capsules.

Pop it in the fridge. Take it daily. Leave time travel to the mice until human trials arrive.

Frequently asked questions

Did scientists discover an anti-ageing probiotic?

They identified a bacterium associated with younger microbiome patterns in human cohorts and found that giving it to aged mice improved several ageing-related measurements. No human supplementation trial was conducted, so it is not a proven anti-ageing probiotic for people.

What is Bifidobacterium pseudocatenulatum?

Bifidobacterium pseudocatenulatum is a bacterial species found in the human gut. The study found that it was less abundant with increasing age across the analysed Chinese cohorts.

What benefits were found in mice?

Aged mice receiving the bacterium showed improvements in intestinal homeostasis, inflammatory markers across several organs, cognitive and motor tests, and measures of healthspan. Mouse findings do not guarantee the same effects in people.

What is 5-AVAB?

5-AVAB is short for 5-aminovaleric acid betaine, a metabolite associated with microbial and dietary metabolism. It reproduced some of the bacterium’s effects in aged mice, but it was not tested as an anti-ageing treatment in people.

Does healthspan mean the mice lived longer?

Not necessarily. Healthspan refers to the period of better function or health. The study reported improvements in several ageing-related measures and described extended healthspan; this should not be converted into a claim of longer human lifespan.

Can probiotics prevent dementia or frailty?

This study does not show that probiotics prevent or treat dementia, frailty or mobility problems in people. Clinical trials using specific strains and meaningful human outcomes would be required.

Was Noster ProBiotics tested?

No. Noster ProBiotics were not used in the human observations or mouse experiments. The findings cannot be attributed to the Noster formulation.

The friendly pharmacist’s final word

This Nature Aging paper is exactly the sort of research that makes microbiome science exciting.

Researchers connected a bacterium that declined with age in human cohorts to a plausible metabolite and then tested both in naturally aged mice. The bacterium improved intestinal, inflammatory, cognitive and motor measurements, while 5-AVAB reproduced some of those effects.

That is an impressive scientific pathway from observation to mechanism.

It is not a human anti-ageing treatment.

The responsible conclusion is:

Bifidobacterium pseudocatenulatum and its metabolite produced promising ageing-related effects in mice. Human studies have so far shown associations—not proof that taking this or any commercial probiotic slows human ageing.

The elderly mice may enjoy their moment in the spotlight. Grandma’s fountain of youth remains irritatingly unavailable.

Resources

• Nature Aging: A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan
• Nature Portfolio reporting summary
• Chinese Academy of Sciences: Research summary
• World Health Organization: Ageing and health
• NCCIH: Probiotics—usefulness and safety

This article provides general educational information and does not replace individual medical advice, diagnosis or treatment from your doctor, pharmacist or other qualified healthcare professional.